The Centers for Medicare and Medicaid Services (CMS) has released a draft decision outlining proposed coverage guidelines for Aduhelm, a controversial drug that is supposed to slow cognitive decline in early-stage Alzheimer's patients. According to the Washington Post, Medicare plans to cover the drug, but only for patients participating in clinical studies approved by CMS or supported by the National Institutes of Health. The drug, which is currently priced at $28,000 per year, has been a subject of intense controversy, with critics questioning its effectiveness. A final decision will be issued by April 11.
Related Posts
Nutcrackers highlight Christmas traditions
Simple Christmas treats of oranges and nuts thrilled children throughout history, and the remnants of those traditions are still with us in decorative…
Study links gum disease to breast cancer
A common bacteria associated with gum disease may cause DNA damage and speed breast tumor growth, according to a new study from the Johns Hopkins Cancer…
Good sleep habits encourage rest
If you do the same things every night before you sleep, you can expect to fall asleep faster and sleep deeper. Called Sleep Hygiene, these considerations…